Cara Palermo
Family · Clearwater, FLNPI 1740816438
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$909
- AbbVie$679
- Lilly USA, LLC$669
- AstraZeneca$404
- Amgen$380
- Pfizer$318
- plus $3K from 28 others
What the payments were for
- Food & beverage$6,158100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $909 |
| AbbVie | 39 | $679 |
| Lilly USA, LLC | 38 | $669 |
| AstraZeneca | 23 | $404 |
| Amgen | 23 | $380 |
| Pfizer | 16 | $318 |
| Bayer | 14 | $315 |
| Boehringer Ingelheim | 10 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $194 |
| Merck | 10 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $183 |
| Neurocrine Biosciences, Inc. | 7 | $171 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $160 |
| Novartis | 8 | $140 |
| Dexcom, Inc. | 6 | $131 |
| GSK | 7 | $124 |
| Amarin Pharma, Inc. | 6 | $118 |
| Sanofi-aventis U.S. LLC | 6 | $98 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Scilex Pharmaceuticals Inc. | 4 | $84 |
| Kowa Pharmaceuticals America, Inc. | 5 | $74 |
| Eisai Inc. | 4 | $67 |
| Esperion Therapeutics, Inc. | 3 | $62 |
| Johnson & Johnson | 4 | $56 |
| Exact Sciences | 3 | $55 |
| Sumitomo Pharma America, Inc. | 5 | $42 |
| Astellas Pharma US Inc | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Acerus Pharmaceuticals Corporation | 2 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| Corcept Therapeutics | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $14 |
How this compares
$6,172 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 21 | $31,170 |
| FarxigaDapagliflozin Propanediol | 12 | $9,167 |
| Rosuvastatin Calcium | 26 | $264 |
| Omeprazole | 11 | $213 |
| Levothyroxine Sodium | 27 | $184 |
| Fluticasone Propionate | 12 | $155 |
| Losartan Potassium | 13 | $153 |
| Amlodipine Besylate | 23 | $145 |
| Tamsulosin Hcl | 11 | $92 |
| Alendronate Sodium | 12 | $88 |
| Sertraline Hcl | 15 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $679 | $31,17021 claims |
| AstraZenecaFarxiga | $404 | $9,16712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $18427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Clearwater
- Marian FinehirshClearwater$31K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.